Preview

Медицинский Совет

Расширенный поиск

ТАРГЕТНАЯ ТЕРАПИЯ БРЕНТУКСИМАБОМ ВЕДОТИНОМ ПРИ ЛЕЧЕНИИ РЕЦИДИВОВ И РЕФРАКТЕРНЫХ ФОРМ КЛАССИЧЕСКОЙ ЛИМФОМЫ ХОДЖКИНА

https://doi.org/10.21518/2079-701X-2017-14-88-92

Полный текст:

Аннотация

Современные  программы терапии первой линии позволяют излечить около 80% больных классической лимфомой Ходжкина при любой стадии заболевания, однако 10–30%  больных оказываются рефрактерными и нуждаются в продолжении лечения. Стандартом лечения рецидивов или резистентных форм классической лимфомы Ходжкина является химиотерапия второй линии с высокодозной консолидацией под защитой аутологичных  стволовых клеток крови, но эффективность такой терапии не превышает 50% для всей группы рефрактерных больных. Появление препаратов таргетного действия, специфичных для опухолевых клеток Березовского – Рид – Штернберга, открывает новые перспективы в лечении классической лимфомы Ходжкина. В статье приводится обзор исследований по применению нового таргетного препарата брентуксимаба ведотина при лечении рецидивов и рефрактерных форм классической лимфомы Ходжкина.

Об авторе

Е. А. Демина
Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России
Россия

Доктор медицинских наук,  профессор.

Москва



Список литературы

1. De Vita VT. The consequences of the chemotherapy of Hodgkin’s disease: the 10th David A. Karnofsky memorial lecture. Cancer, 1981, 47: 1-13. doi: 10.1002/1097-0142(19810101)47:1<1::AIDCNCR2820470102>3.0.

2. Engert A, Younes A, editors. Hematologic malignancies: Hodgkin lymphoma. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg. Springer, 2015. DOI 10.1007/978-3-319-12505-3.

3. Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Onco, 2008, 20: 118. DOI: 10.1155/2014/605691.

4. Falini B, Pileri S, Pizzolo G, et al: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood, 1995, 85: 1-14. DOI: http://dx.doi.org/

5. Matsumoto K, Terakawa M, Miura K, et al: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol, 2004, 172: 2186-2193. doi: 10.4049/jimmunol.172.4.2186.

6. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol, 2007, 25: 2764-2769. doi: 10.1200/JCO.2006.07.8972.

7. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol, 2009, 146: 171-179. doi: 10.1111/j.1365-2141.2009.07740.x.

8. Dosio F, Brusa P and Cattel L Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins, 2011, 3: 848-883. doi: 10.3390/toxins3070848.

9. Francisco JA., Cerveny CG., Meyer DL. Et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 2003, 102: 1458-1465. published ahead of print April 24, 2003. DOI: http://dx.doi.org/10.1182/blood-2003-01-0039.

10. Sutherland MSK, Sanderson RJ, Gordon KA, et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*. The Journal of Biological Chemistry, 2006 April 14, 281(15): 10540–10547, DOI 10.1074/jbc.M510026200.

11. Katz J, Janik JA, Yones A. Brentuximab vedotin (SGN-35). Clin Cancer Res, 2011, 17: 6428-6436. doi: 10.1158/1078-0432.CCR-11-0488.

12. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. FiveYear Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clin Adv Hematol Oncol, 2016 Feb, 14(2 Suppl 1): 6. PMID: 27007002 [PubMed in process] doi: 10.1200/JCO.2011.38.0410.

13. Younes A, Gopal AK, Smith SE et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol, 2012, 30: 2183-2189. doi: .1200/JCO.2011.38.0410.

14. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma, 2013, 54: 2531–33. doi: 10.3109/10428194.2013.798868

15. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 2015, 125(8): 1236-1243 doi:10.1182/blood-2014-08-595801.

16. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol, 24: 1633-1642, 2006. doi: 10.1200/JCO.2005.04.0543.

17. Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008, 6: 455-467.

18. Zinzani PL, Corradini P, Gianni AM., et al Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper Clinical Lymphoma, Myeloma & Leukemia. Elsevier Inc, 2015, 15(9): 507-13.

19. Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30ю hematologic malignancies: the German Hodgkin Study Group experience. Blood, 2012, 120: 1470-2. doi:10.1182/blood-2012-05-430918.

20. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30 lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica, 2013. doi:10.3324/haematol.2012.069393.

21. Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica, 2013, 98: 1232-6.

22. Perrot A, Monjanel H, Bouabdallah R, et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica, 2014, 99(s1), 498: abstr S1293, PMID: 25768991.

23. Perrot A, Monjanel H, Bouabdallah R, et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica, 2016 Apr, 101(4):466-73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan14.

24. Moskowitz CH, Yahalom J, Zelenetz AD et al. High-Dose Chemo-Radiotherapy for Relapsed or Refractory Hodgkin Lymphoma and the Significance of Pre-transplant Functional Imaging. Br J Haematol, 2010 Mar, 148(6): 890–897. Published online 2010 Jan 18. doi: 10.1111/j.1365-2141.2009.08037.x

25. Moskowitz A, Schoder H, Gerecitano JF. FDG-PET Adapted Sequential Therapy with Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant for Relapsed and Refractory Hodgkin Lymphoma. Blood, 2013, 122(21): 2099. DOI: http://dx.doi.org/

26. Moskowitz AJ, Hamlin PA Jr, Perales M-A, et al. Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. JCO, 2013 February 1, 31(4): 456-460; doi: 10.1200/JCO.2012.45.3308.

27. LaCasce A, Sawas A, Bociek RG, et al. A phase 1/2 single-arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma in the first salvage setting: interim results [abstract]. Biol Blood Marrow Transplant, 2014, 20(2): S161. Published Online: 7:32 PM, Mon December 8, 2014.

28. Aparicio J, Segura A et al. ESHAP is an Active Regimen for Relapsing Hodgkin’s Disease. Annals of Oncology, 10(5): 593-5, June 1999. DOI: 10.1023/A:1026454831340

29. Garcia-Sans R, et al. Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood, 2015, DOI: Published 3 December 2015.

30. Bartlett N, Brice P, Chen RW et al. Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study. J Clin Oncol, 2012, 30(suppl; abstr 8027). Annual Meeting Abstracts. 30(15_suppl) (May 20 Supplement), 2012.

31. Batlevi CL and Younes A, Novel therapy for Hodgkin lymphoma. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY. doi: 10.1182/asheducation-2013.1.394.

32. Moskowitz CH, Paszkiewicz-Kozik E, Nadamanee A, et al. Analisis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled sdudy of brentuximab vedotin consolidation after autologous stem cell transplant. Hematol Oncol, 2015, 33: 165, abstr 120.

33. Moskowitz CH, Nademanee A, Masszi T, and al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2015, March 18, 385(9980): 1853–1862. Published online: doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.

34. Walewski JA, Nademanee A, Masszi T et al., Multivariate analisis of PFS from the AETHERA trail: a phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. ASCO June 2015, Chocago Illinoice USA, abstr 8519.

35. Sweetenham JW, Walewski J, Nadamanee A et al. Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Biol Blood Marrow Transplant, 2016, 22: S19e-S481, abstr 24. DOI:dx.doi.org/10.1016/j.bbmt.2015.11.315


Просмотров: 136


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)